Disclosures for "Quantitative Assessment of Remyelination by Q-space Myelin Map and its Association With Functionality and Quality of Life in Multiple Sclerosis"
-
Dr. Pimentel has nothing to disclose.
-
Dr. Mora has nothing to disclose.
-
Dr. Sommer has nothing to disclose.
-
Miss Gallo has nothing to disclose.
-
Mr. Neves has nothing to disclose.
-
Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra-Zeneca. The institution of Dr. Sato has received research support from Biogen. The institution of Dr. Sato has received research support from Merck.